Experimental cell infusion aims to tame childhood autoimmune diseases
NCT ID NCT07439029
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial will test a new cell therapy called YTS109 in 12 children aged 5 to 17 with severe autoimmune diseases like lupus or scleroderma that have not responded to standard treatments. The children will receive a single infusion of these cells, and researchers will monitor safety and any signs of improvement. The goal is to see if this approach is safe and might help control these serious conditions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- YTS109 cell therapy (a type of cell infusion)
- What this could lead to
- If it works, this could point toward a new treatment option for children with hard-to-treat autoimmune diseases like lupus or scleroderma.
- What could go wrong
- This is a very early, small Phase 1 trial with only 12 children, so it may not show clear benefit or could have unexpected side effects. The therapy is experimental and not yet proven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANCA ASSOCIATED VASCULITIS (AAV) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Children's Hospital of Fudan University
Shanghai, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Three-Drug combo quiet lupus kidney flares?
- Can a new antibody tame lupus flares?
- Can a targeted antibody tame kidney inflammation without heavy steroids?
- Can a single infusion of reprogrammed immune cells quiet lupus kidney disease?
- Engineered immune cells take aim at Hard-to-Treat autoimmune diseases
- Eye tests could spot silent vision damage in lupus patients